Consensus recommendations from the American Acne & Rosacea Society on the Management of Rosacea, Part 3: A status report on systemic therapies

James Q. Del Rosso, Diane Thiboutot, Richard Gallo, Guy Webster, Emil Tanghetti, Lawrence F. Eichenfield, Linda Stein-Gold, Diane Berson, Andrea Zaenglein

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

The third article in this 5-part series reviews systemic therapies used to treat cutaneous rosacea based on consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. The consensus recommendations are based on current understanding of research that describes pathophysiologic mechanisms that appear to be operative in rosacea, correlation of these underlying pathophysiologic mechanisms with specific clinical manifestations of rosacea, and outcomes from clinical trials that evaluate therapies for rosacea both as monotherapy and in combination with other agents. Systemic agents used for treatment of rosacea have been administered as oral formulations (ie, tablets, capsules). The only oral agent for rosacea approved by the US Food and Drug Administration (FDA) is a modified-release doxycycline 40-mg capsule. Other non-FDA-approved oral agents also are discussed including other tetracyclines, macrolides, metronidazole, and isotretinoin.

Original languageEnglish (US)
Pages (from-to)18-28
Number of pages11
JournalCutis
Volume93
Issue number1
StatePublished - Jan 2014

All Science Journal Classification (ASJC) codes

  • Dermatology

Fingerprint Dive into the research topics of 'Consensus recommendations from the American Acne & Rosacea Society on the Management of Rosacea, Part 3: A status report on systemic therapies'. Together they form a unique fingerprint.

Cite this